OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The aim is to create new genomics solutions that could combat cancer and advance market access
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
If approved it will bring a second source of MMR vaccine to the US market
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Subscribe To Our Newsletter & Stay Updated
